Viking Therapeutics (VKTX) Retained Earnings (2014 - 2026)
Viking Therapeutics (VKTX) posted Retained Earnings of -$1.1 billion for Q2 2026, down 12.73% sequentially from -$1.0 billion in Q1 2026, and down 89.27% YoY from -$10.6 billion in Q2 2025.
Viking Therapeutics (VKTX) Retained Earnings (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Retained Earnings for 13 years, with the latest figure at -$1.1 billion in Q2 2026.
- Quarterly Retained Earnings fell 89.27% year-over-year to -$1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.1 billion (down 89.27% YoY) and the FY2025 annual result came in at -$847.5 million, down 73.71% from the prior year.
- Retained Earnings slipped to -$1.1 billion in Q2 2026 per VKTX's latest filing, from -$1.0 billion in the prior quarter.
- Over five years, Retained Earnings peaked at -$239.3 million in Q1 2022 and troughed at -$1.1 billion in Q2 2026.
- A 5-year average of -$501.0 million and a median of -$416.4 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings decreased 28.06% in 2024, then plunged 89.27% in 2026.
- Over 5 years, Retained Earnings stood at -$292.0 million in 2022, then declined by 29.41% to -$377.9 million in 2023, then retreated by 29.1% to -$487.9 million in 2024, then slumped by 73.71% to -$847.5 million in 2025, then slumped by 33.79% to -$1.1 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.1 billion, -$1.0 billion, and -$847.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -1.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.13 Bn |
| Mar 31, 2026 | -1.01 Bn |
| Dec 31, 2025 | -847.55 Mn |
| Sep 30, 2025 | -689.88 Mn |
| Jun 30, 2025 | -599.10 Mn |
| Mar 31, 2025 | -533.54 Mn |
| Dec 31, 2024 | -487.91 Mn |
| Sep 30, 2024 | -452.49 Mn |
| Jun 30, 2024 | -427.55 Mn |
| Mar 31, 2024 | -405.30 Mn |
| Dec 31, 2023 | -377.94 Mn |
| Sep 30, 2023 | -353.34 Mn |
| Jun 30, 2023 | -330.81 Mn |
| Mar 31, 2023 | -311.58 Mn |
| Dec 31, 2022 | -292.05 Mn |
| Sep 30, 2022 | -272.49 Mn |
| Jun 30, 2022 | -256.72 Mn |
| Mar 31, 2022 | -239.29 Mn |
| Dec 31, 2021 | -223.18 Mn |
| Sep 30, 2021 | -210.83 Mn |